Rocket Pharmaceuticals Inc (RCKT) is trading 10% higher at $15.5 today. So far the Health Care sector has been having a mildly positive day, and the share price of the company is quickly outpacing it's peers.
-Rocket's gene therapy for heart disease appears to be effective in children and adults, based on the results of a phase 1 clinical trial.
-The therapy involves injecting a modified version of a patient's own cells into their heart.
-So far, the treatment has been well tolerated and appears to be safe.
Earnings are a long way off, so that is unlikely to be moving the share price.
Rocket Pharmaceuticals Inc has been trading between a 52-week high of $36.87 and a 52-week low of $7.57. The stock has a market cap of $1.02 Billion.
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases.
Rocket Pharmaceuticals PT Raised to $75 at Evercore ISI
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Business Wire 09-30-22
Rocket Pharmaceuticals Inc. (RCKT) can beat the pack with these strategies
US Post News 09-27-22
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
Business Wire 09-27-22
The M&A Class Action Firm Announces an Investigation of Renovacor, Inc. - RCKT
Kwhen Finance 09-22-22